Baseline patient-reported outcomes of ABioPharm patients, comparing self-identified indigenous to non-indigenous participants. Reported as n (%) or mean (SD) as appropriate, and p value reported only for significantly different values between groups.
| Indigenous, n = 90 | Non-indigenous, n = 1400 | p | |
|---|---|---|---|
| PtGA, 0–10 | 7.1 (2.2) | 6.6 (2.2) | 0.05 |
| Pain, 0–10 | 7.6 (2.2) | 6.7 (2.2) | < 0.0001 |
| Fatigue, 0–10 | 7.1 (2.4) | 6.6 (2.6) | |
| Sleep, 0–10 | 7.2 (2.9) | 6.0 (3.0) | < 0.0001 |
| HAQ, 0–3 | 1.7 (0.6) | 1.6 (0.6) | 0.002 |
| Stiffness, min | 120 (173) | 93 (144) | 0.0022 |
| EQ-5D | 0.3 (0.3) | 0.4 (0.3) | 0.001 |
| SF-36 physical health, standardized | 25.3 (9.2) | 26.9 (9.0) | 0.05 |
| SF-36 mental health, standardized | 40.1 (12.1) | 45.3 (11.9) | 0.0002 |
ABioPharm: Alberta Biologics Pharmacosurveillance Program; PtGA: patient’s global assessment; HAQ: Health Assessment Questionnaire; SF-36: Medical Outcomes Study Short Form-36.